CB Therapeutics is the World Leader in the Biosynthetic Production of Two of the Most Promising Families of Compounds in Neuroscience to Improve Mental Healthcare

Clinical research on these compounds has been suppressed over the last half a century but now new regulatory frameworks are creating a significant clinical and market opportunity.

CB Therapeutics is continuing to refine its platform and advance its pipeline for the development and production of a library of these two families of molecules, their analogs as well as others showing therapeutic promise in neuroscience. We are partnering with top hospitals on clinical trials for these high therapeutic value biosynthetic compounds.